PHC Granted Product Registration in Brazil

RNS Number : 7882S
Plant Health Care PLC
13 July 2015
 

13 July 2015


 

 

 

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

Plant Health Care's Technology Granted Product Registration in Brazil

 

Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce that it has received its first product registration in Brazil from the Brazilian Ministry of Agriculture. With this registration, the Company and its partners will be allowed to sell products based on its current generation of commercialized protein technology for foliar use on all crops.

 

Plant Health Care's protein technology is now approved for usage in 12 countries, including Brazil and the United States, which represent the two largest agricultural markets in the world. In addition, this registration allows the Company to move forward with the development and distribution agreement it signed with Arysta LifeScience in December, 2014 for foliar application of its technology to sugarcane in Brazil. Under that contract, Arysta LifeScience agreed to evaluate the Company's current protein technology across a range of geographical locations throughout Brazil and generate detailed information on increased biomass and sucrose production. In earlier studies, the technology showed significant and reliable increases in sugarcane yield. Pending consistent and reliable test results in the evaluation program, first sales of the product in Brazil are anticipated in the 2017 crop season.

 

Paul Schmidt, CEO of Plant Health Care, commented, "This registration is very significant to Plant Health Care as Brazil is the single largest agricultural market in the world. Sugarcane is one of the country's most important crops, covering more than 20 million acres, and a feedstock for the production of ethanol, which is a major component of Brazil's renewable fuel policy. Arysta LifeScience is a strong partner for the sugarcane market and we see the potential to establish a formidable position in this important sector."

 

João Marcos Ferrari, President & CEO of Arysta LifeSciences Do Brasil, commented, "We are excited to move forward with Plant Health Care in this collaborative effort. We have seen this technology provide significant increases in yield and sugar production in sugarcane and believe it will offer substantial benefits to growers. This is another important step toward our goal to be a leader in the applications of biological products in agricultural production."

 

The Company will issue interim results for the six months to June 30, 2015 on September 14, 2015.

 

- ENDS -

For further information, please contact:

Plant Health Care plc

Paul Schmidt, Chief Executive Officer                                                    Tel: +1 (919) 926 1600

 

Liberum Capital - Nomad and Broker

Clayton Bush                                                                                                     Tel: +44 (0) 20 3100 2000

 

LHA

Ed McGregor / Jody Burfening                                                                  Tel: +1 (212) 838 3777

 

Company website: www.planthealthcare.com

 

About Plant Health Care:  Plant Health Care is a leading provider of novel patent-protected biological products to the global agriculture markets.  In this way, Plant Health Care is capitalising on long-term trends toward natural systems and biological products for plant care and soil and water management.  The Company's ordinary shares have been quoted on the AIM market of the London Stock Exchange since July 2004 (ticker symbol: PHC). 

 

About Arysta LifeScience:  Arysta LifeScience, now owned by Platform Specialty Products, is a leading crop protection and life science company with 2014 revenues of US$2.2 billion. An entrepreneurial provider of crop protection and life science products in more than 125 countries worldwide, Arysta LifeScience specializes in marketing and distribution of respected crop protection brands and life science products that meet the needs of its global partners. 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEALXEFSXSEFF
UK 100

Latest directors dealings